Tumor mutational burden (TMB) is an important biomarker for predicting response to immunotherapy, but should clinicians rely on blood-based or tissue-based testing? In this episode, Suneel Kamath, MD discusses research comparing blood and tissue TMB across solid tumors and their ability to predict immunotherapy outcomes. He explains why blood TMB levels are often higher than tissue TMB, why tissue testing remains the stronger predictor of treatment benefit and how disease-specific blood TMB thresholds could improve clinical decision-making in the future.